PATTERN OF LIVER-DISEASE FOLLOWING HIGH-DOSE CYTOSINE-ARABINOSIDE (HDARAC) THERAPY IN CHILDREN WITH ACUTE MYELOID-LEUKEMIA

被引：4

作者：

LOCASCIULLI, A

UDERZO, C

PIROLA, A

MASERA, G

PORTMANN, B

ALBERTI, A

机构：

[1] KINGS COLL HOSP & MED SCH,LIVER UNIT,LONDON,ENGLAND

[2] UNIV PADUA,MED CLIN 2,IST MED CLIN,I-35100 PADUA,ITALY

[3] UNIV MILAN,OSPED S GERARDO,PEDIAT CLIN,MONZA,ITALY

来源：

LEUKEMIA & LYMPHOMA | 1990年 / 2卷 / 3-4期

关键词：

Acute myeloid leukemia; Ara-C; HBV infection;

D O I：

10.3109/10428199009053528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The occurrence of liver disease and its relation to HBV markers were investigated in ten children with AML who were given HDARAC as late consolidation therapy. None of them developed jaundice or biochemical evidence of cholestasis. During therapy, SGPT values were normal in 5/10 patients, while in the other 5 a sharp increase was noted. These enzyme elevations followed an unusual timing, peaking just before each infusion of HDARAC. Evidence of long-lasting hepatocellular necrosis after therapy withdrawal was found in 8/8 cases. One child died of fulminant type B hepatitis and HBsAg positivity was found in 2/10 patients during therapy and 3/8 after withdrawal of the drug. Three children developed HBV antibodies during the observation period. We conclude that the use of HDARAC in childhood leukemia is not associated with major evidence of direct drug hepatotoxicity while it clearly affects the natural outcome of viral hepatitis © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：229 / 233

页数：5

共 17 条

[1]

Degos B.L., Castaigne S., Tilly H., Sigaua Daniel M., Treatment of leukemia with low-dose ARa-C: a study of 160 cases, Sent Onc, 12, pp. 196-199, (1985)

[2]

Rudnick S.A., Cadman E.C., Capizzi R.L., High dose Cytosine Arabinoside (HDARAC) in refractory acute leukemia, Cancer, 44, pp. 1189-1193, (1979)

[3]

Ettinger L.S., Biener R., Finklestein J.Z., Sequential high-dose Cytosine Arabinoside and L-Aspara ginase in childhood leukemia in relapse, Sent Onc, 12, pp. 155-159, (1985)

[4]

Hines J.D., Oken M.M., Mazza J., Keller A., Glick J., High-dose Cytosine Arabinoside and M-AMSA in refractory acute non-lymphocitic leukemia, Blood, 58, (1981)

[5]

Cappizi R.L., Poole M., Cooper M.R., Treatment of poor risk acute leukemia with sequential high-dose Ara-C and Asparaginase, Blood, 63, pp. 694-700, (1984)

[6]

Messner H.A., Curtis J.E., Minder M.M., The combiner use of Cytosine Arabinoside, Cyclophosphamide and total body irradiation as preparative regimen for bone marrow transplantation in patients with AML and CML, Sem Onc, 12, pp. 287-290, (1985)

[7]

Pizzuto J., Aviles A., Ramos E., Cervera J., Aguirre J., Cytosine Arabinoside induced liver damage:histopatho logical demonstration, Med Fed One, 11, pp. 287-290, (1983)

[8]

George C.B., Mansour R.P., Redmond G., Gandara D.R., Hepatic dysfunction and jaundice following high-dost Cytosine Arabinoside, Cancer, 54, pp. 2360-2362, (1984)

[9]

Locasciulli A., Mieli Vergani G., Uderzo C., Chronic liver disease in children with leukemia in long-term remission, Cancer, 52, pp. 1080-1087, (1983)

[10]

Locasciulli A., Alberti A., Rossetti F., Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Pediatric Cooperative Group for therapy of acute leukemia (AIL-AIEOP), Med Ped. Onc, 13, pp. 203-206, (1985)

← 1 2 →